Table 3.
Clinical data on Crohn’s disease patients
| Patients | |
| Sex (M/F) | 34/33 |
| Age at surgery (y) | 36.7 (4.0) |
| Time between diagnosis of fistula and surgery (months) | 4.0 (37.9) |
| Prior medical treatment for fistular disease | |
| Antibiotics | 10 (11.9%) |
| Azathioprine | 5 (6%) |
| Oral 5-ASA derivatives | 6 (7.1%) |
| Systemic glucocorticoids | 12 (14.3%) |
| Topical 5-ASA derivates | 1 (1.2%) |
| Cyclophosphamide | 1 (1.2%) |
| Cyclosporin | 1 (1.2%) |
| Infliximab | 1 (1.2%) |
| Mycofenolat mofetile | 1 (1.2%) |
| Present medication | |
| Antibiotics | 29 (34.5%) |
| Azathioprine | 10 (11.9%) |
| Oral 5-ASA derivatives | 27 (32.1%) |
| Systemic glucocorticoids | 42 (50%) |
| Topical 5-ASA derivatives | 2 (2.4%) |
| Topical glucocorticoids | 0 (0%) |
| Cyclosporin | 0 (0%) |
| E coli Nissle | 1 (1.2%) |
| Infliximab | 0 (0%) |
| Methotrexate | 1 (1.2%) |
| Location of fistula | |
| Ileum | 50 (59.5%) |
| Colon | 26 (31%) |
| Perianal | 8 (9.5%) |
| Concomitant complication | |
| None | 27 (32%) |
| Abscess | 26 (31%) |
| Conglomerate tumour | 24 (28.6%) |
| Peritonitis | 7 (8.3%) |